Therapeutic peptides are becoming increasingly important within the pharma industry and currently represent a market value of 28 billion USD with an annual growth rate of at least 10% over the next five years. Pepscan has developed a unique technology to discover new highly constrained peptides with enhanced affinity, selectivity and proteolytic stability suited for diagnostic and therapeutic applications. Phage display is a technology that allows for the de novo discovery of peptides against any target of interest by exploring …

Annually thousands of pharma and biotech companies launch a clinical trial to evaluate the efficacy and safety of their potential new therapeutic or diagnostic tool. BiOrion is one of the companies that will take its first step in this clinical trajectory this year (2020) with their targeted peptide treating fibrotic diseases. Getting ready for the clinic“It is very exciting being able to enter the clinic. Therefore, we were looking for a reliable expert partner who is able to manufacture our …

Pepscan’s Precision Epitope Mapping Platform provides scientists the ability to identify the best peptide leads from large collections of patient sera and to pinpoint strain-specific or region-specific differences in immune responses. This platform is one of the tools in the search for a COVID-19 vaccine to subdue the current pandemic. “Using Pepscan’s CLIPS Precision Epitope Mapping Platform, we can screen patient and control samples to assess whether distinct epitopes are prevalent in patient sera. The addition of conformational peptide mapping …

“Our drive to move forward combined with a positive spirit and creativity are important assets” “As an employee of Pepscan for almost 15 years, I have worked on several challenges regarding Pepscan’s continuous drive for development and improvement. I’m glad that we also overcame our latest challenge: providing our customers with on-schedule and high-quality deliveries while working under COVID-19 guidelines,” says Richard van Duinkeren, Team Lead Analytics at Pepscan. Keeping up the pace and delivery schedules As soon as the …

Benefit from an unprecedented choice of library sizes and rapid delivery times Peptide libraries are widely applied as a powerful tool in biological research. Peptide libraries provide a rapid and cost-effective solution for a broad range of bioactivity-screening purposes, like identification of critical bioactive peptides which could serve, for example, as lead for a new COVID-19-related vaccine. Pepscan is the founder of peptide library technology and has over 25 years of experience in designing, synthesizing, and utilizing custom peptide libraries. …

We would like to inform you that the Pepscan facility is operational. This allows us to proceed serving and supporting scientists in their work on amongst others diagnostic and vaccine related COVID-19 projects and treatment of cancer patients with personalized peptide vaccines. By implementing a shift-schedule and additional precautionary measures to minimize physical interaction amongst our staff, we are able to continue the production and delivery of R&D and clinical peptides so far. Our sales team works offsite, but strives …

Learn about Pepscan’s phage display technology used to discover highly constrained peptides with enhanced affinity, selectivity and proteolytic stability. April 2nd – 16.00 CEST – 10.00 ET – 7.00 PT Register here We invite you to join our upcoming webinar featuring Pepscan experts Prof. Peter Timmerman and Dr. Michael Goldflam sharing their expertise on de novo discovery of the best peptide binders for your target protein of interest.  This webinar will discuss Pepscan’s proprietary phage display CLIPSTM technology platform, which …

Therapeutic targeting of the VEGF signaling axis by the VEGF neutralizing monoclonal antibody bevacizumab has clearly demonstrated clinical benefit in cancer patients. To improve this strategy using a polyclonal approach, a vaccine targeting VEGF was developed for medical oncology using 3D-structured peptides that mimic the bevacizumab binding site. “Before the start of this RVO-funded project a small research group, including myself, had developed a general approach to protein-mimics using scaffold-technology. We wanted to apply this approach to the mimicry of …

“Being able to discover and develop new therapeutics is what makes me passionate about my work!” “In the upcoming period I would like to combine my knowledge and experience with Pepscan’s Phage Display technology and team, to take my new employer’s Peptide Discovery platform to the next level, aiming to boost drug discovery and development,” says Sangram Kale, who recently started as Scientist at Pepscan. Sangram originally comes from India, where he completed his Master and PhD degrees in Organic …

Why Pepscan is the provider of epitope mapping services in 58% of last year’s European patent publications Mapping the epitopes of an antibody is an inevitable step in therapeutic antibody development. Epitope mapping not only serves intellectual property purposes, but also provides the data needed for antibody selection and characterization and gives the information needed for FDA and EMA regulatory filings. Dennis Flierman and Martin Ham visited the 2019 Antibody Engineering & Therapeutics Conference in San Diego and spotted the …